Jubilant Pharma Limited, an integrated pharmaceutical company, manufactures and markets active pharmaceutical ingredients (APIs), dosage forms, radiopharmaceuticals, and allergy therapy products. It operates in Contract Development and Manufacturing Operations, Specialty Pharmaceuticals, and Generics segments. The company offers APIs in the therapeutic areas of the cardiovascular system (CVS), central nervous system (CNS), anti-infectives, anti-diabetic, etc.; and solid dosage formulations for CVS, CNS, GI, and anti-allergy therapeutic categories. It also provides radiopharmaceuticals for diagnostic imaging of cardiology, oncology, lung, kidney, brain, and bone, as well as radiotherapy for thyroid and cancer; and allergy therapy products, such as allergenic extracts and mixes, and a line of specialized skin test devices, as well as venom extracts. In addition, the company offers contract manufacturing services of sterile injectables, ophthalmics, otics, sterile and non-sterile ointments, creams, and liquids; and insect venom products for the treatment of allergies to insect stings. Jubilant Pharma Limited offers its products in North America, Europe, Asia, and internationally. It has a strategic partnership with SOFIE Biosciences, Inc. to advance its theranostic pipeline, and support novel PET diagnostic manufacturing and distribution. The company was incorporated in 2005 and is based in Singapore. Jubilant Pharma Limited is a subsidiary of Jubilant Life Sciences Limited.
Contour is building the world’s open trade finance network. By focusing on collaboration and leveraging new technologies we are dissolving the barriers to seamless trade. Our networks of banks, corporates, services and partnerships enable the instant flow of trusted data across the world’s trade routes and current fragmented ecosystems.
Contour is building the world’s open trade finance network. By focusing on collaboration and leveraging new technologies we are dissolving the barriers to seamless trade. Our networks of banks, corporates, services and partnerships enable the instant flow of trusted data across the world’s trade routes and current fragmented ecosystems.
Private Equity Round in 2016
Phoon Huat & Co (Pte) Ltd. engages in the wholesale supply of bakery, beverage, and confectionery ingredients. It also operates specialty stores for housewives, cafes, and restaurants. The company was founded in 1947 and is based in Singapore with specialty stores in Singapore.
Navigat Group (“Navigat” or the “Company”) is Indonesia’s leading distributed power plant developer, owner and operator with 265MW of installed capacity and has other operations in Thailand and Myanmar. Navigat is also the second largest global distributor of General Electric (“GE) Jenbacher power equipment having sold over 1,000MW of units in South East Asia, with the distribution license for these products in Indonesia, Singapore and Thailand. The top holding company is incorporated in Singapore with the Company’s headquarters in Jakarta and substantially all its operations in Indonesia. The Company’s main focus is the distributed gas to power market in South East Asia (“SEA”), and it typically pursues power projects of 5 – 100MW in size. Through its two major divisions, Navigat Energy (GE Jenbacher gas engine equipment sales and service) and MAXPower (IPP, BOOT and Rental projects), Navigat has the ability to fully exploit distributed power opportunities along the value chain from equipment sales, to services, to construction management, to project development and asset ownership.